evaluate novo nordisk on glp-1 agonists Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies Avono Health | GLP-1 Explained:

In 2023, Humphrey and Lawrence emphasized the importance for plastic surgeons to recognize these potential effects, counsel patients before initiating therapy, and consider both surgical and non-surgical interventions to mitigate facial volume loss, sagging, and premature aging [86]

Preclinical studies have demonstrated that DPP-4 inhibitors significantly prevent the onset of liver cancer in MC4R-KO mice [111]

In patients with IIH, abrupt cessation of GLP-1RA therapy has been reported to lead to a return of symptoms or new onset IIH in two separate case reports, highlighting the requirement of continuous therapy (22,24)

doi: 10.3390/molecules27134315, 14

Free fatty acids act on receptors including GPR 43, GPR119 and GPR 120, and FFAR (29, 51, 113), and proteins may act through the Ca 2+ sensing receptor (CaSR) which responds to amino acids (24) or the peptide transporter PepT1 (69)

Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis